Examining Deucrictibant's Effectiveness in Managing HAE
At the recent Bradykinin Symposium 2024, Pharvaris (Nasdaq: PHVS) shared impressive long-term extension data on deucrictibant, a new oral bradykinin B2 receptor antagonist aimed at treating hereditary angioedema (HAE). This information not only reinforces the safety and tolerability established in Phase 2 studies but also positions deucrictibant as a leading candidate for both preventive and on-demand treatment of HAE.
Preventive Advantages of Deucrictibant
The long-term data on prophylaxis revealed that participants experienced a remarkable 93% decrease in HAE attacks after more than a year of treatment. This significant reduction highlights deucrictibant's potential to provide enduring relief and greatly enhance the quality of life for those living with HAE. Furthermore, many participants reported a median attack rate that dropped to zero, underscoring the effectiveness of this treatment option.
Insights from the Bradykinin Symposium
During the symposium, Dr. Peng Lu, CMO of Pharvaris, highlighted the treatment's quick onset of action as particularly promising. The median time for symptom relief was noted to be just 1.1 hours, with most attacks completely resolving within 24 hours. These findings were supported by a propensity score-matched analysis, which favorably compared deucrictibant to standard care. Such compelling data strongly suggests that deucrictibant is effectively meeting the needs of HAE patients.
Efficiency of On-Demand Treatment
When it comes to on-demand treatment, deucrictibant offers significant benefits. Participants in the studies not only experienced a fast onset of symptom relief but also a notable decrease in attack severity. Specifically, the median time for complete resolution of attacks was recorded at just 11.5 hours. With an impressive 85.8% of attacks resolving in under 24 hours, deucrictibant emerges as a timely and effective option for acute HAE episodes.
Focusing on Health-Related Quality of Life
As Dr. Marc Riedl emphasized, the primary aim of managing HAE is to enable individuals to live without restrictions. Deucrictibant stands out as a strong option, not only enhancing treatment effectiveness but also increasing overall patient satisfaction. The ongoing collection of health-related quality of life data will provide further insights into the comprehensive benefits of this innovative treatment.
Future Plans for Pharvaris
With encouraging data coming from both Phase 2 studies on prophylaxis and on-demand treatment, Pharvaris is actively moving forward with the development of deucrictibant. A pivotal Phase 3 study for on-demand treatment is currently enrolling participants, and plans for a separate Phase 3 study for prophylaxis are in progress. This important transition reflects Pharvaris's dedication to offering effective solutions for all forms of bradykinin-mediated angioedema.
Frequently Asked Questions
What is deucrictibant?
Deucrictibant is an oral bradykinin B2 receptor antagonist developed by Pharvaris for the treatment of hereditary angioedema (HAE).
How significantly does deucrictibant reduce HAE attacks?
Long-term use of deucrictibant has shown to reduce the attack rate by 93% compared to baseline in clinical studies.
What are the benefits of deucrictibant for on-demand treatment?
Deucrictibant provides rapid symptom relief with a median onset time of approximately 1.1 hours and high rates of complete resolution within 24 hours.
What are the ongoing studies for deucrictibant?
Pharvaris is currently enrolling participants for a pivotal Phase 3 study for on-demand treatment and will soon initiate a Phase 3 study for prophylaxis.
How does deucrictibant affect quality of life for HAE patients?
Clinical data suggests that deucrictibant improves treatment satisfaction and overall quality of life for individuals managing HAE symptoms.
